Merus/$MRUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
$MRUS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
291
ISIN
NL0011606264
Website
Merus Metrics
BasicAdvanced
$3.9B
-
-$4.14
0.95
-
Price and volume
Market cap
$3.9B
Beta
0.95
52-week high
$62.98
52-week low
$33.19
Average daily volume
1.6M
Financial strength
Current ratio
5.86
Quick ratio
5.337
Long term debt to equity
1.356
Total debt to equity
1.653
Profitability
EBITDA (TTM)
-298.553
Gross margin (TTM)
-17.37%
Net profit margin (TTM)
-506.73%
Operating margin (TTM)
-549.95%
Effective tax rate (TTM)
-3.32%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-30.61%
Return on equity (TTM)
-58.66%
Valuation
Price to revenue (TTM)
64.823
Price to book
6.15
Price to tangible book (TTM)
6.17
Price to free cash flow (TTM)
-14.792
Free cash flow yield (TTM)
-6.76%
Free cash flow per share (TTM)
-358.23%
Growth
Revenue change (TTM)
42.77%
Earnings per share change (TTM)
50.98%
3-year revenue growth (CAGR)
1.45%
10-year revenue growth (CAGR)
44.88%
3-year earnings per share growth (CAGR)
30.42%
10-year earnings per share growth (CAGR)
-4.21%
What the Analysts think about Merus
Analyst ratings (Buy, Hold, Sell) for Merus stock.
Bulls say / Bears say
Citigroup raised its price target for Merus from $89.00 to $97.00, maintaining a 'buy' rating, indicating strong confidence in the company's growth potential. (etfdailynews.com)
Merus announced a 67% response rate in combination with pembrolizumab in first-line head and neck squamous cell carcinoma (HNSCC), showcasing promising clinical trial results. (stocktitan.net)
The company successfully raised $460 million in a public offering, extending its cash runway into 2028, providing substantial financial stability for future operations. (stocktitan.net)
Merus reported a Q4 loss of $0.41 per share, missing revenue estimates by 22.35%, indicating potential financial challenges. (nasdaq.com)
The company experienced a 13.5% decline in short interest as of February 15th, suggesting increased bearish sentiment among investors. (americanbankingnews.com)
Merus set a new 12-month low, trading as low as $33.19, reflecting potential concerns about its stock performance. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Merus Financial Performance
Revenues and expenses
Merus Earnings Performance
Company profitability
Merus News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merus stock?
Merus (MRUS) has a market cap of $3.9B as of June 30, 2025.
What is the P/E ratio for Merus stock?
The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of June 30, 2025.
Does Merus stock pay dividends?
No, Merus (MRUS) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Merus dividend payment date?
Merus (MRUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Merus?
Merus (MRUS) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.